biotechnology

Biotech Stocks: Here's Where to Get In: Peregrine Pharmaceuticals …

Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]

Biotech Stocks You Should Dump: Ariad Pharmaceuticals, Inc …

Investors have been flocking to biotech stocks this year, with the IBB, the ETF that tracks biotech stocks, making noteworthy gains. So far in 2015, several industries have either underperformed or provided mixed results, leading to a rather ho-hum showpiece for U.S. blue-chip indices.Biotech stocks, on the other hand, have consistently returned positive results in the markets over the past […]

Fear These Three Biotech Stocks: AVEO Pharmaceuticals, Inc …

They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]

Biotech Stocks: Here's Where to Get In: Omeros Corporation …

The S&P 500 Biotech Index has nearly tripled in the past three years. The index had stalled and moved sideways for much of the past spring, leading some to wonder whether the rally was spent. Several factors have been fueling the biotech rally of the past three years. For one thing, the U.S. Food and Drug Administration has been pushing […]

Biotech Stocks to bet on: Incyte Corporation (NASDAQ:INCY …

They say good things come in threes. If so, biotech companies could be in for not just another year of outperformance, but another decade. The first era of biotech was a building phase, when companies created their first blockbuster drugs. The second, current one, has resulted in a four-year rally that reflects the sector’s transition from a cluster of one-hit […]

The Historical Correlation Between Biotech Stocks And … – Benzinga

Related AMGNSocial Media Beat: What The Crowd & Experts Think Of Oil, Biotech & LinkedInStocks Hitting 52-Week HighsAre You Ready For A Pullback BIIB AMGN GILD CELG UTHR JAZZ GOOG FB NFLX APA APC EOG PANW DO RIG(Marketfy Insights)Related CELG5 Biotechs With Catalysts Coming This WeekIs More M&A On The Way For Large-Cap Biotechs?Are You Ready For A Pullback BIIB […]

This is Why Amgen is Soaring

By Ben LevisohnInvestors love biotech stocks, but heading into July, Amgen (AMGN) was unloved, especially compared to its other biotech giants like Regeneron Pharmaceuticals (REGN), Gilead Sciences (GILD) and Biogen (BIIB). No longer. Shares of Amgen have jumped nearly 6% after reporting better than forecast earnings and raising its guidance. UBS analyst Matthew Roden has the details:
Amgen reported another strong […]

These are the Biggest Risk to Biotech – Stocks to Watch – Barrons.com

By Ben LevisohnIn a note this morning, BofA Merrill Lynch’s Christina Giannini and team note that the risk for big-cap biotech stocks–think Gilead Sciences (GILD) and Biogen (BIIB)–and small-cap biotech stocks–everything else–are quite different. They explain:
Associated Press

Biotech is now more passive than actively managed: Perhaps due to the difficulty picking stocks within such an idiosyncratic sector given the complicated science […]

Biotech Stocks: Safe vs Sexy

By Johanna BennettDo you want safe, or sexy?That’s the question facing biotechnology investors, according to a recent research note from Cowen analysts that previews the sector’s second-quarter financial results.“In heady times, large cap provides a safe haven, smid caps the sex appeal,” reads the note.After shrugging off a selloff in late June, the Nasdaq Biotechnology index has gained 30% since […]

Janet Yellen comments on biotech valuations in 2014 – Business …

Janet Yellen is facing Congress on Wednesday for her semi-annual testimony.And one year ago today, Yellen’s monetary policy report warned about stock market valuations, particularly in social media and biotech stocks. It was an awful call. Yellen’s testimony last year said:”Some broad equity price indexes have increased to all-time highs in nominal terms since the end of 2013. However, valuation measures for the overall market in […]